A Phase 2 interventional study of Abemaciclib and Trastuzumab in Hormone Receptor Positive Breast Cancer and HER-2 Positive Breast Cancer, sponsored by Eli Lilly and Company. Completed at 93 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 5 that started in 2016, is one of 27 in phase 2, and was the 7th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 237 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 24th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2016, is one of 41 in phase 2, and was the 54th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
previously received:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
Drug: Abemaciclib · Drug: Trastuzumab · Drug: Fulvestrant
150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
Drug: Abemaciclib · Drug: Trastuzumab
8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
Drug: Trastuzumab · Drug: Standard of Care Single Agent Chemotherapy
Administered Orally
Also known as: LY2835219
Administered IV
Administered IM
Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
Progression Free Survival (PFS)
PFS time was measured from the date of randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: Baseline to Progressive Disease or Death from Any Cause (Up To 36 Months)
Percentage of Participants With 1 Year Overall Survival (OS)
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 1 year from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.
Time frame: Randomization to date of death from any cause assessed at 1 year
Percentage of Participants With 2 Year OS
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 2 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.
Time frame: Randomization to date of death from any cause assessed at 2 years
Percentage of Participants With 3 Year OS
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 3 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.
Time frame: Randomization to date of death from any cause assessed at 3 years
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: Baseline to Objective Disease Progression (Up To 36 Months)
Duration of Response (DoR)
DoR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.
Time frame: Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up To 36 Months)
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.
Time frame: Baseline to Objective Disease Progression (Up To 36 Months)
Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months: Clinical Benefit Rate (CBR)
Clinical benefit rate defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \*100.
Time frame: Date of CR, PR or SD to 6 Months Post CR, PR or SD (Up To 36 Months)
Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
The mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes. Mean Interference Score data is reported here. Least square (LS) Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which were anchored on a scale of 0 to 1 with a higher score representing better health status.LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The EQ-5D-5L is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. A higher score indicates better health state. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20)
Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20) was evaluated. M2 and M20 are 2 major active metabolites of abemaciclib.
Time frame: Cycle(C)1 Day(D)1,C1D15, C2D1, C2D8, C3D1,C3D15, C4D1, C5D1:pre-dose; C1D1, C2D1, C3D1, C4D1, C5D1:post-dose
| Milestone | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Started | 79 | 79 | 79 |
| Received at least one dose of drug | 78 | 77 | 72 |
| Completed | 74 | 71 | 74 |
| Not completed | 5 | 8 | 5 |
| Withdrew: Withdrawal by subject | 2 | 4 | 2 |
| Withdrew: Lost to follow-up | 3 | 4 | 3 |
PFS time was measured from the date of randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
| Months | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Progression Free Survival (PFS) | 8.3 (5.9 to 12.6) | 5.7 (4.2 to 7.2) | 5.7 (5.4 to 6.9) |
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 1 year from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.
| percentage of participants | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Percentage of Participants With 1 Year Overall Survival (OS) | 77.2 (65.9 to 85.2) | 77.4 (66.1 to 85.3) | 69.8 (57.5 to 79.1) |
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 2 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.
| percentage of participants | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Percentage of Participants With 2 Year OS | 55.8 (43.5 to 66.4) | 55.7 (43.4 to 66.3) | 43.0 (30.9 to 54.5) |
OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 3 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.
| percentage of participants | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Percentage of Participants With 3 Year OS | 46.7 (34.7 to 57.9) | 40.2 (28.6 to 51.5) | 29.9 (19.1 to 41.3) |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| Percentage of participants | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR) | 32.9 (22.5 to 43.3) | 13.9 (6.3 to 21.6) | 13.9 (6.3 to 21.6) |
DoR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.
| Months | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Duration of Response (DoR) | 12.5 (6.5 to 23.5) | 9.5 (2.8 to 22.7) | NA (4.1 to NA) |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.
| Percentage of participants | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR) | 78.5 (69.4 to 87.5) | 74.7 (65.1 to 84.3) | 67.1 (56.7 to 77.5) |
Clinical benefit rate defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \*100.
| Percentage of participants | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months: Clinical Benefit Rate (CBR) | 58.2 (47.4 to 69.1) | 45.6 (34.6 to 56.6) | 38.0 (27.3 to 48.7) |
The mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes. Mean Interference Score data is reported here. Least square (LS) Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
| units on a scale | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf) | 0 ± 0.18 | 0.20 ± 0.18 | 0.31 ± 0.19 |
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
| units on a scale | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Global health status | -2.9 ± 1.6 | -5.9 ± 1.7 | -1.9 ± 1.8 |
| Functional scale: Physical functioning | -1.0 ± 1.6 | -4.4 ± 1.6 | -4.5 ± 1.7 |
| Functional scale: Role functioning | -2.7 ± 2.2 | -5.0 ± 2.3 | -8.2 ± 2.4 |
| Functional scale: Emotional functioning | 2.4 ± 1.7 | -0.4 ± 1.8 | 1.1 ± 1.8 |
| Functional scale: Cognitive functioning | -1.8 ± 1.4 | -1.1 ± 1.5 | -1.6 ± 1.6 |
| Functional scale: Social functioning | -0.9 ± 1.9 | -0.9 ± 1.9 | -2.4 ± 2.0 |
| Symptom scale: Fatigue | 1.8 ± 1.9 | 7.0 ± 2.0 | 4.7 ± 2.1 |
| Symptom scale: Nausea and vomiting | 6.3 ± 1.4 | 5.6 ± 1.4 | 2.2 ± 1.5 |
| Symptom scale: Pain | -2.5 ± 2.1 | 3.1 ± 2.1 | 4.3 ± 2.2 |
| Symptom scale: Dyspnoea | 0.7 ± 1.9 | 2.9 ± 2.0 | 3.7 ± 2.1 |
| Symptom scale: Insomnia | -4.4 ± 2.1 | -1.6 ± 2.2 | 2.0 ± 2.3 |
| Symptom scale: Appetite loss | 6.3 ± 2.3 | 5.5 ± 2.4 | 2.4 ± 2.5 |
| Symptom scale: Constipation | -6.3 ± 1.9 | -10.5 ± 1.9 | -3.4 ± 2.0 |
| Symptom scale: Diarrhoea | 21.5 ± 2.2 | 25.3 ± 2.3 | 2.2 ± 2.4 |
| Symptom scale: Financial difficulties | 0.8 ± 2.0 | -1.9 ± 2.1 | -3.2 ± 2.2 |
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which were anchored on a scale of 0 to 1 with a higher score representing better health status.LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
| units on a scale | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score | 0.01 ± 0.02 | -0.01 ± 0.02 | -0.04 ± 0.02 |
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The EQ-5D-5L is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. A higher score indicates better health state. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
| millimeter (mm) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) | 0.61 ± 1.4 | -1.64 ± 1.4 | -0.61 ± 1.5 |
Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20) was evaluated. M2 and M20 are 2 major active metabolites of abemaciclib.
| nanogram/milliliter (ng/mL) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab |
|---|---|---|
| Abemaciclib | 134 ± 77 | 155 ± 53 |
| M2 | 72.0 ± 120 | 96.5 ± 120 |
| M20 | 136 ± 120 | 181 ± 130 |
Collected over Baseline till end of follow-up (Up to 6.5 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 52/78 (66.7%) | 24/78 (30.8%) | 76/78 (97.4%) |
| 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 55/77 (71.4%) | 15/77 (19.5%) | 75/77 (97.4%) |
| 8 mg/kg Trastuzumab + Standard of Care Chemotherapy | 53/72 (73.6%) | 14/72 (19.4%) | 68/72 (94.4%) |
| Event | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/78 | 0/77 | 3/72 |
| SepsisInfections and infestations | 1/78 | 0/77 | 3/72 |
| PneumoniaInfections and infestations | 1/78 | 2/77 | 2/72 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/78 | 0/77 | 2/72 |
| DiarrhoeaGastrointestinal disorders | 1/78 | 2/77 | 0/72 |
| PyrexiaGeneral disorders | 2/78 | 1/77 | 0/72 |
| GastroenteritisInfections and infestations | 2/78 | 0/77 | 0/72 |
| Acute kidney injuryRenal and urinary disorders | 2/78 | 1/77 | 0/72 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/78 | 0/77 | 0/72 |
| LeukopeniaBlood and lymphatic system disorders | 0/78 | 0/77 | 1/72 |
| Event | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 62/78 | 60/77 | 18/72 |
| FatigueGeneral disorders | 45/78 | 41/77 | 32/72 |
| NeutropeniaBlood and lymphatic system disorders | 38/78 | 27/77 | 26/72 |
| NauseaGastrointestinal disorders | 38/78 | 32/77 | 26/72 |
| AnaemiaBlood and lymphatic system disorders | 30/78 | 20/77 | 16/72 |
| Abdominal painGastrointestinal disorders | 24/78 | 19/77 | 16/72 |
| ThrombocytopeniaBlood and lymphatic system disorders | 23/78 | 23/77 | 5/72 |
| VomitingGastrointestinal disorders | 22/78 | 22/77 | 11/72 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/78 | 12/77 | 9/72 |
| Decreased appetiteMetabolism and nutrition disorders | 19/78 | 16/77 | 13/72 |
All enrolled participants.
| Age, Continuous(years) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy | Total |
|---|---|---|---|---|
| Mean | 54.34 ± 10.25 | 54.99 ± 11.08 | 56.77 ± 12.37 | 55.37 ± 11.27 |
| Sex: Female, Male(Participants) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy | Total |
|---|---|---|---|---|
| Female | 79 | 79 | 79 | 237 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 11 | 12 | 37 |
| Not Hispanic or Latino | 58 | 52 | 56 | 166 |
| Unknown or Not Reported | 7 | 16 | 11 | 34 |
| Race (NIH/OMB)(Participants) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 15 | 10 | 10 | 35 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 4 | 9 |
| White | 55 | 53 | 55 | 163 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 6 | 13 | 8 | 27 |
| Region of Enrollment(Participants) | 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant | 150 mg Abemaciclib + 8 mg/kg Trastuzumab | 8 mg/kg Trastuzumab + Standard of Care Chemotherapy | Total |
|---|---|---|---|---|
| Argentina | 9 | 7 | 3 | 19 |
| United States | 20 | 8 | 17 | 45 |
| United Kingdom | 9 | 9 | 10 | 28 |
| Spain | 6 | 8 | 3 | 17 |
| Greece | 1 | 1 | 2 | 4 |
| Canada | 2 | 4 | 4 | 10 |
| South Korea | 11 | 9 | 10 | 30 |
| Belgium | 5 | 7 | 7 | 19 |
| Brazil | 3 | 1 | 4 | 8 |
| Italy | 2 | 5 | 2 | 9 |
| Mexico | 2 | 1 | 3 | 6 |
| Australia | 2 | 4 | 2 | 8 |
| France | 6 | 13 | 8 | 27 |
| Germany | 1 | 2 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2016 to primary completion in Apr 2019, 34 months.
Results were first posted in May 2020, 1 year 1 month after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 34 months is close to that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib